OpenScience.ink

1 week ago • Appetite

How activating or blocking one receptor differently affects effectiveness and side effects in obesity treatmentOne receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.

📖 Top 20% Journal

1 week ago • Clinical case reports

Allergic reaction to tirzepatide with tolerance to semaglutide: a case reportHypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.

1 week ago • Frontiers in neurology

GLP-1 receptor drugs may improve movement and mood in Parkinson's disease: a combined analysisGLP-1 receptor agonists in Parkinson's disease: a meta-analysis revealing motor benefit and highlighting mood improvement.

📖 Top 20% Journal

1 week ago • AACE endocrinology and diabetes

Changes in Prescriptions of Two Diabetes Medicines for Type 2 Patients from 2014 to 2024Trends in Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024.

1 week ago • American journal of translational research

Liraglutide and pioglitazone treatment in obese polycystic ovary syndrome and its impact on blood levels of chemerin and visfatinClinical efficacy of liraglutide combined with pioglitazone in obese polycystic ovary syndrome and its effects on the serum chemerin/visfatin ratio.

1 week ago • JACC. Advances

Reduced Risk of Heart and Brain Blood Vessel Problems with Semaglutide Compared to TirzepatideCardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.

🎖️ Top 10% Journal

1 week ago • Journal of the neurological sciences

Use of glucagon-like peptide-1 receptor activators linked to severity of ischemic strokeAssociation between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity.

📖 Top 20% Journal

1 week ago • Obesity pillars

Satisfaction and experience with once-weekly tirzepatide treatment from doctors and people with obesity or overweightReal-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.

📖 Top 20% Journal

1 week ago • Internal and emergency medicine

Semaglutide's effects on thinking skills in people with type 2 diabetes and mild memory problems over 24 monthsImpact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study.

1 week ago • Frontiers in endocrinology

How Albiglutide Affects Heart Muscle Contraction in Humans and MiceContractile effects of albiglutide in the human and mouse atrium.

🎖️ Top 10% Journal

1 week ago • Journal of endocrinological investigation

New Findings on Protein Changes Linked to Semaglutide in Humans and AnimalsAdvances in proteomics research related to semaglutide: evidence from humans and animals.

📖 Top 20% Journal

1 week ago • Pharmacology & therapeutics

Using Biomarkers to Guide Drug Choice and Monitoring in Heart, Kidney, and Metabolic ConditionsBiomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring.

2 weeks ago • Obesity surgery

Cost-effectiveness of minimally invasive weight loss treatments compared to sleeve stomach surgery and semaglutideCost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.

📖 Top 20% Journal

2 weeks ago • Frontiers in endocrinology

Effectiveness and safety of oral GLP-1 medicines for type 2 diabetes and obesityInvestigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis.

🎖️ Top 10% Journal

2 weeks ago • Rheumatology international

GLP-1 receptor drugs in joint and psoriatic diseases: a possible connection between obesity and inflammationGLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?

📖 Top 20% Journal

2 weeks ago • Journal of food and drug analysis

Can semaglutide affect tumor markers? Evidence from a patient caseCan semaglutide influence tumor biomarkers? Insight from a clinical case.

📖 Top 30% Journal

2 weeks ago • Obesity reviews : an official journal of the International Association for the Study of Obesity

Heart health effects of GLP-1 medicines in people with overweight and obesity: A review of clinical trial summariesCardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.

2 weeks ago • Indian journal of orthopaedics

Possible Uses of Glucagon-Like Peptide-1 Receptor Drugs in Bone and Joint CareGlucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.

📖 Top 50% Journal

2 weeks ago • Mayo Clinic proceedings

Alcohol Use After Treatment with GLP-1 Receptor Agonists in the Cooper Center StudyAlcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study.

2 weeks ago • Journal of endocrinological investigation

Survival and ongoing treatment in older adults with type 2 diabetes taking gliflozins or incretin drugsMortality and persistence in therapy in elderly subjects with type 2 diabetes receiving gliflozins or incretins.

📖 Top 20% Journal

2 weeks ago • Cardiovascular diabetology. Endocrinology reports

Using SGLT2 inhibitors and GLP-1 receptor agonists together in heart failure patientsConcomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.

2 weeks ago • JAMA network open

Starting Semaglutide Treatment in People Using Hormonal Birth ControlHormonal Contraception and Initiation of Semaglutide Therapy.

🥈 Top 2% Journal

2 weeks ago • Biological psychiatry

Possible Benefits of Incretin-Based Treatments for Alcohol Use Disorder Based on Clinical EvidenceTherapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence.

🥈 Top 2% Journal

2 weeks ago • Archives of endocrinology and metabolism

Effects and safety of GLP-1 receptor drugs in kidney transplant patients with diabetes after transplantGLP-1 receptor agonists in kidney transplant recipients with post-transplant diabetes: efficacy and safety outcomes from a retrospective cohort study.

📖 Top 50% Journal

2 weeks ago • The lancet. Gastroenterology & hepatology

Effects of the dual glucagon and GLP-1 receptor drug DD01 on fatty liver disease and liver inflammation: 12-week results from a controlled clinical trialThe glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.

🥇 Top 1% Journal

2 weeks ago • Biological psychiatry

GLP-1 Receptor Drugs as a Possible Treatment for Opioid Addiction: Studies from Rats to HumansGLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.

🥈 Top 2% Journal

2 weeks ago • BMJ open

Link between GLP-1 receptor drugs and alcohol-related hospital visits in adults with alcohol use disorderAssociation between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.

📖 Top 20% Journal

2 weeks ago • Diabetes research and clinical practice

Glucagon-like peptide-1 receptor drugs and new cases of irregular heartbeat in adults with diabetes or obesityGlucagon-like peptide-1 receptor agonists and new-onset atrial fibrillation in adults with diabetes or obesity: a multinational cohort study.

🎖️ Top 10% Journal

2 weeks ago • Diabetes, obesity & metabolism

Safety Warnings for GLP-1 Receptor Agonists from Multiple Drug Safety Databases (2018–2025) with Bias Checks and Prioritized Risk LevelsSafety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.

2 weeks ago • Translational research : the journal of laboratory and clinical medicine

How SGLT2 inhibitors and GLP-1 receptor agonists work together in treating chronic kidney diseaseFrom FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists.

🥉 Top 5% Journal

← prevpage 7 of 14next →

Latest GLP-1 Therapies Research Papers